Predominant inhibition of Th1 cytokines in New Zealand black/white F1 mice treated with FK506

References

• Mosmann TR, Sad S. The expanding universe of T-cell subsets: Thl, Th2 and more. Immunol Today 1996;17:138–46.
   PubMedGoogle Scholar
• Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986;136:2348–57.
   Google Scholar
• Yoshii H, Yamamoto K, Okudaira H, Dohi M, Suko M, Fukata Y, et al. Age-related differential mRNA expression of T cell cytokines in NZB/NZW Fl mice. Lupus 1995;4:213–6.
   PubMed Web of Science ®Google Scholar
• Gutierrez-Ramos JC, Andreu JL, Revilla Y, Vinuela E, Martinez C. Recovery from autoimmunity of MRL/lpr mice after infection with an interleukin-2/vaccinia recombinant virus. Nature 1990;346: 271–4.
   Google Scholar
• Kino T, Hatanaka H, Hashimoto M, Nishiyama M, Goto T, Okuhara M, et al. FK-506, a novel immunsouppressant isolated from a Streptomyces. 1. Fermentation, isolation, and physico-chemical and biological characteristics. J Antibiotics 1987;40: 1249–55.
   Google Scholar
• Ho S, Clipstone N, Timmermann L, Northrop J, Graef I, Fiorentino D, et al. The mechanism of action of cyclospoin A and FK506. Clin Immunol Immunopathol 1996;80:40–5.
   PubMedGoogle Scholar
• Kronke M, Leonard WJ, Depper JM, Arya SK, Wong-Staal F, Gallo RC, et al. Cyclosporin A inhibits T-cell growth factor gene expression at the level of mRNA transcription. Proc Natl Acad Sci USA 1984;81:5214–8.
   Google Scholar
• Undre NA, Stevenson P, Schafer A. Fujisawa GmbH, Munich, Germany. Pharmacokinetics of tacrolimus: clinically relevant aspects. Transplant Proc 1999;31:21–4.
   Google Scholar
• Takabayashi K, Koike T, Kurasawa K, Matsumura R, Sato T, Tomioka H, et al. Effect of FK-506, a novel immuno-suppressive drug on murine systemic lupus erythematosus. Clin Immunol Immunopathol 1989;51:110–7.
   PubMedGoogle Scholar
• Carrieri G, Murase N, Woo J, Nalesnik M, Azzarone A, Funakoshi Y, et al. Effect of FK506 in the prophylaxis of autoimmune glomerulonephritis in NZB/WF1 mice. Trans-plant Proc 1991;23:3357–9.
   PubMed Web of Science ®Google Scholar
• Inamura N, Hashimoto M, Nakahara K, Aoki H, Yamaguchi I, Kohsaka M. Immunosuppressive effect of FK506 on collagen-Induced arthritis in rats. Clin Immunol Immuno-pathol 1988;46:82–90.
   PubMedGoogle Scholar
• Zheng W, Flavell RA. The transcription factor GATA-3 is necessary and sufficient for Th2 cytokine gene expression in CD4 T cells. Cell 1997;89:587–96.
   PubMed Web of Science ®Google Scholar
• Nakajima A, Hirose S, Yagita H, Okumura K. Roles of IL-4 and IL-12 in the development of lupus in NZB/W Fl mice. J Immunol 1997;158:1466–72.
   PubMed Web of Science ®Google Scholar
• Ishida H, Muchamuel T, Sakaguchi S, Andrade S, Menon S, Howard M. Continuous administration of anti-interleukin 10 antibodies delays onset of autoimmunity in NZB/WF1 mice. J Exp Med 1994;179:305–10.
   PubMed Web of Science ®Google Scholar
• Jacob CO, van der meide PH, McDevitt HO. In vivo treatment of (NZB x NZW) Fl lupus-like nephritis with monoclonal antibody to gamma interferon. J Exp Med 1987;166:798–803.
   PubMed Web of Science ®Google Scholar
• Balomenos D, Rumold R, Theofilopoulos AN. Interferon-gamma is required for lupus-like disease and lymphoaccumula-tion in MRL-Ipr mice. J Clin Invest 1998;101:364–71.
   Google Scholar
• Haas C, Ryffel B, Le Hir M. IFN-y receptor deletion prevents autoantibody production and glomerulonephritis in lupus-prone (NZB x NZW) Fl mice. J Immunol 1998;160:3713–8.
   Google Scholar
• Schwarting A, Wada T, Kinoshita K, Tesch G, Kelley YR. IFN-gamma receptor signaling is essential for the initiation, acceleration, and destruction of autoimmune kidney disease in MRL-Fas (1pr) mice. J Immunol 1998;161: 494–503.
   Google Scholar
• Funauchi M, Ikoma S, Horiuchi A. Decreased Thl-like and increased Th2-like cells in systemic lupus erythematosus. Scand J Rheumatol 1998;27: 219–24.
   Google Scholar
• Smolen JS, Tohidast-Akrad M, Gal A, Kunaver M, Eberl G, Zenz P, et al. The role of T-lymphocyte and cytokines in rheumatoid arthritis. Scand J Rheumatol 1996;25:1–4.
   PubMed Web of Science ®Google Scholar
• Konttinen YT, Kemppinen P, Koski H, Li TF, Jumppanen M, Hietanen J, et al. T(H)1 cytokines are produced in labial salivary glands in Sjogren's syndrome, but also in healthy individuals. Scand J Rheumatol 1999;28:106–12.
   PubMed Web of Science ®Google Scholar
• Ikezumi Y, Kanno K, Koike H, Tomita M, Uchiyama M, Shimizu F, et al. FK506 ameliorates proteinuria and glomerular lesions induced by anti-Thy 1.1 monoclonal antibody 1-22-3. Kidney Int 2002;61:1339–50.
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Mori A, Nakahama T, Ito M, Okudaira H, Miyamoto T. Experimental treatment of autoimmune MRL-lpr/lpr mice with immunosuppressive compound FK506. Immunology 1990;69:222–7.
   PubMed Web of Science ®Google Scholar
• Dumont FJ, Staruch MJ, Koprak SL, Melino MR, Sigal NH. Distinct mechanisms of suppression of murine T cell activation by the related macrolides FK-506 and rapamycin. J Immunol 1990;144: 251–8.
   Google Scholar
• Gajewski TF, Schell SR, Fitch FW. Evidence implicating utilization of different T cell receptor-associated signaling pathway by TH1 and TH2 clones. J Immunol 1990;144: 4110–20.
   Google Scholar
• Bossie A, Vitetta ES. IFN-gamma enhances secretion of IgG2a from IgG2a- committed LPS-stimulated murine B cells: implications for the role of IFN-gamma in class switching. Cell Immunol 1991;135:95–104.
   PubMed Web of Science ®Google Scholar
• Armitage RJ, Macduff BM, Springgs MK, Fanslow WC. Human B cell proliferation and Ig secretion induced by recombinant CD40 ligand are modulated by soluble cytokines. J Immunol 1993;150:3671–80.
   PubMed Web of Science ®Google Scholar
• Suzuki N, Sakane T, Tsunematsu T. Effect of a novel immunosuppressive agent,FK506, on human B cell activation. Clin Exp Immunol 1990;79: 240–5.
   Google Scholar
• Walliser P, Benzie CR, Kay JE. Inhibition of murine B-lymphocyte proliferation by the novel immunosuppressive drug FK-506. Immunology 1989;68: 434–5.
   Google Scholar
• Takahashi S, Nose M, Sakaki J, Yamamoto T, Kyogoku M. IgG3 production in MRL/Ipr mice is responsible for development of lupus nephritis. J Immunol 1991;147: 515–9.
   Google Scholar